New mechanism identified disarms the macrophages that attack the immune cells. A substance called Gdf-15 released by pancreatic tumor cells suppresses macrophage during early tumor development, reveals a new study.
The study found that the substance Gdf-15, might be required for the development of early pancreatic tumors. The research also revealed that a molecule pronounced N-F-kappa-B (NF-kB) helps tumor cells produce Gdf-15.
The new study was by researchers at The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute (OSUCCC - James).
The findings are reported in the Journal of Clinical Investigation.
"This study shows that GDF-15 plays an important role in the development of pancreatic cancer and might be required for the development of early pancreatic tumors," says principal investigator Denis Guttridge, PhD, professor of Cancer Biology and Genetics at Ohio State and associate director for basic research.
"We believe that this mechanism for disarming macrophages develops early in cancer cells, enabling small tumors to survive and grow," adds Guttridge, who also is in the OSUCCC - James Molecular Carcinogenesis and Chemoprevention Program.
"These findings support the need for preclinical studies to determine the role of GDF-15 in the development of pancreatic cancer."
Guttridge and his colleagues conducted the study using pancreatic-cancer cell lines, cells from patient tumors and an animal model.
Key findings include:
- NF-kB is a direct regulator of Gdf-15
- GDF-15 suppresses macrophage cell-killing activity by inhibiting the production of nitric oxide and tumor necrosis factor
- Both GDF-15 and NF-kB are overexpressed in patients with pancreatic cancer
"Overall," Guttridge says, "our results reveal that NF-kB is responsible for the synthesis and secretion of GDF-15 from pancreatic tumor cells, and that GDF-15 then inhibits NF-kB activity in macrophages and blocks them from killing tumor cells."